Inhibition of hepatitis C virus RNA replicons by peptide aptamers

Antiviral Research

Volumn 77, Issue 3, 2008, Pages 195-205

  Trahtenherts, Alla ^a   Gal Tanamy, Meital ^a   Zemel, Romy ^a   Bachmatov, Larisa ^a   Loewenstein, Shelly ^a   Tur Kaspa, Ran ^a,b   Benhar, Itai ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

HCV; Liver diseases; NS3 serine protease; Peptide aptamers; RNA replicons

Indexed keywords

NONSTRUCTURAL PROTEIN 3; PEPTIDE APTAMER; SERINE PROTEINASE; VIRUS RNA;

ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC SCREENING; GENETIC TRANSFECTION; GENOMICS; HEPATITIS C VIRUS; IMMUNIZATION; IN VITRO STUDY; LIFE CYCLE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; VIRUS CHARACTERIZATION; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS VIRULENCE;

ANTIVIRAL AGENTS; APTAMERS, PEPTIDE; CELL LINE; DRUG EVALUATION, PRECLINICAL; HEPACIVIRUS; HUMANS; PROTEASE INHIBITORS; RNA, VIRAL; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

BACTERIA (MICROORGANISMS); HEPATITIS C VIRUS;

EID: 38749089014     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.12.013     Document Type: Article

References (75)

1. Bach H., Mazor Y., Shaky S., Shoham-Lev A., Berdichevsky Y., Gutnick D.L., and Benhar I. Escherichia coli maltose-binding protein as a molecular chaperone for recombinant intracellular cytoplasmic single-chain antibodies. J. Mol. Biol. 312 (2001) 79-93
2. Baines I.C., and Colas P. Peptide aptamers as guides for small-molecule drug discovery. Drug Discov. Today 11 (2006) 334-341
3. Barbas III C.F., Bain J.D., Hoekstra D.M., and Lerner R.A. Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 4457-4461
4. Bartenschlager R., Kaul A., and Sparacio S. Replication of the hepatitis C virus in cell culture. Antiviral Res. 60 (2003) 91-102
5. Bartenschlager R., and Sparacio S. Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus Res. 127 (2007) 195-207
6. Berdichevsky Y., Zemel R., Bachmatov L., Abramovich A., Koren R., Sathiyamoorthy P., Golan-Goldhirsh A., Tur-Kaspa R., and Benhar I. A novel high throughput screening assay for HCV NS3 serine protease inhibitors. J. Virol. Methods 107 (2003) 245-255
7. Borghouts C., Kunz C., and Groner B. Peptide aptamers: recent developments for cancer therapy. Expert Opin. Biol. Ther. 5 (2005) 783-797
8. Borowski P., Heiland M., Feucht H., and Laufs R. Characterisation of non-structural protein 3 of hepatitis C virus as modulator of protein phosphorylation mediated by PKA and PKC: evidences for action on the level of substrate and enzyme. Arch. Virol. 144 (1999) 687-701
9. Borowski P., Kühl R., Laufs R., Schulze zur Wiesch J., and Heiland M. Identification and characterization of a histone binding site of the non-structural protein 3 of hepatitis C virus. J. Clin. Virol. 13 (1999) 61-69
10. Bourne N., Pyles R.B., Yi M., Veselenak R.L., Davis M.M., and Lemon S.M. Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system. Antiviral Res. 67 (2005) 76-82
11. Bréchot C. Hepatitis C virus: molecular biology and genetic variability. Digest Dis. Sci. 41 (1996) 6S-21S
12. Buerger C., Nagel-Wolfrum K., Kunz C., Wittig I., Butz K., Hoppe-Seyler F., and Groner B. Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. J. Biol. Chem. 278 (2003) 37610-37621
13. Butz K., Denk C., Fitscher B., Crnkovic-Mertens I., Ullmann A., Schröder C.H., and Hoppe-Seyler F. Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity. Oncogene 20 (2001) 6579-6586
14. Butz K., Denk C., Ullmann A., Scheffner M., and Hoppe-Seyler F. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 6693-6697
15. Chattopadhyay A., Tate S.A., Beswick R.W., Wagner S.D., and Ko Ferrigno P. A peptide aptamer to antagonize BCL-6 function. Oncogene 25 (2006) 2223-2233
16. Coëffier E., Clément J.M., Cussac V., Khodaei-Boorane N., Jehanno M., Rojas M., Dridi A., Latour M., El Habib R., Barré-Sinoussi F., Hofnung M., and Leclerc C. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 19 (2000) 684-693
17. Cohen B.A., Colas P., and Brent R. An artificial cell-cycle inhibitor isolated from a combinatorial library. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 14272-14277
18. Colas P., Cohen B., Jessen T., Grishina I., McCoy J., and Brent R. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature 380 (1996) 548-550
19. Colas P., Cohen B., Ko Ferrigno P., Silver P.A., and Brent R. Targeted modification and transportation of cellular proteins. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 13720-13725
20. Crawford M., Woodman R., and Ko Ferrigno P. Peptide aptamers: tools for biology and drug discovery. Brief Funct. Genom. Proteom. 2 (2003) 72-79
21. Cui Q., Lim S.K., Zhao B., and Hoffmann F.M. Selective inhibition of TGF-beta responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP. Oncogene 24 (2005) 3864-3874
22. De Francesco R., and Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 436 (2005) 953-960
23. De Francesco R., Tomei L., Altamura S., Summa V., and Migliaccio G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res. 58 (2003) 1-16
24. Dimasi N., Martin F., Volpari C., Brunetti M., Biasiol G., Altamura S., Cortese R., De Francesco R., Steinkühler C., and Sollazzo M. Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires. J. Virol. 71 (1997) 7461-7469
25. Fabbrizio E., Le Cam L., Polanowska J., Kaczorek M., Lamb N., Brent R., and Sardet C. Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity. Oncogene 18 (1999) 4357-4363
26. Failla C., Tomei L., and De Francesco R. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J. Virol. 68 (1994) 3753-3760
27. Ferrières G., Villard S., Pugnière M., Mani J.C., Navarro-Teulon I., Rharbaoui F., Laune D., Loret E., Pau B., and Granier C. Affinity for the cognate monoclonal antibody of synthetic peptides derived from selection by phage display. Role of sequences flanking the binding motif. Eur. J. Biochem. 267 (2000) 1819-1829
28. Frelin L., Brenndörfer E.D., Ahlén G., Weiland M., Hultgren C., Alheim M., Glaumann H., Rozell B., Milich D.R., Bode J.G., and Sällberg M. The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor alpha mediated liver disease. Gut 55 (2006) 1475-1483
29. Gal-Tanamy M., Zemel R., Berdichevsky Y., Bachmatov L., Tur-Kaspa R., and Benhar I. HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen. J. Mol. Biol. 347 (2005) 991-1003
30. Galfrè G., Monaci P., Nicosia A., Luzzago A., Felici F., and Cortese R. Immunization with phage-displayed mimotopes. Methods Enzymol. 267 (1996) 109-115
31. Geyer C.R., and Brent R. Selection of genetic agents from random peptide aptamer expression libraries. Methods Enzymol. 328 (2000) 171-208
32. Hoppe-Seyler F., Crnkovic-Mertens I., Tomai E., and Butz K. Peptide aptamers: specific inhibitors of protein function. Curr. Mol. Med. 4 (2004) 529-538
33. Ishido S., and Hotta H. Complex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor. FEBS Lett. 438 (1998) 258-262
34. Johansson A., Poliakov A., Akerblom E., Lindeberg G., Winiwarter S., Samuelsson B., Danielson U.H., and Hallberg A. Tetrapeptides as potent protease inhibitors of hepatitis C virus full-length NS3 (protease-helicase/NTPase). Bioorg. Med. Chem. 10 (2002) 3915-3922
35. Kakiuchi N., Komoda Y., Komoda K., Takeshita N., Okada S., Tani T., and Shimotohno K. Non-peptide inhibitors of HCV serine proteinase. FEBS Lett. 421 (1998) 217-220
36. Kasai N., Tsumoto K., Niwa S., Misawa S., Ueno T., Hayashi H., and Kumagai I. Inhibition of the hepatitis C virus NS3 protease activity by Fv fragment of antibody 8D4. Biochem. Biophys. Res. Commun. 281 (2001) 416-424
37. Kolonin M.G., and Finley Jr. R.L. Targeting cyclin-dependent kinases in Drosophila with peptide aptamers. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 14266-14271
38. Kwong A.D., Kim J.L., Rao G., Lipovsek D., and Raybuck S.A. Hepatitis C virus NS3/4A protease. Antiviral Res. 40 (1998) 1-18
39. Lindenbach B.D., Evans M.J., Syder A.J., Wölk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., and Rice C.M. Complete replication of hepatitis C virus in cell culture. Science 309 (2005) 623-626
40. Lohmann V., Körner F., Koch J., Herian U., Theilmann L., and Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 (1999) 110-113
41. Lopez-Ochoa L., Ramirez-Prado J., and Hanley-Bowdoin L. Peptide aptamers that bind to a geminivirus replication protein interfere with viral replication in plant cells. J. Virol. 80 (2006) 5841-5853
42. Malcolm B.A., Liu R., Lahser F., Agrawal S., Belanger B., Butkiewicz N., Chase R., Gheyas F., Hart A., Hesk D., Ingravallo P., Jiang C., Kong R., Lu J., Pichardo J., Prongay A., Skelton A., Tong X., Venkatraman S., Xia E., Girijavallabhan V., and Njoroge F.G. SCH 503034 a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob. Agents Chemother. 50 (2006) 1013-1020
43. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., and Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
44. Martin F., Steinkühler C., Brunetti M., Pessi A., Cortese R., De Francesco R., and Sollazzo M. A loop-mimetic inhibitor of the HCV-NS3 protease derived from a minibody. Protein Eng. 12 (1999) 1005-1011
45. Martin F., Volpari C., Steinkühler C., Dimasi N., Brunetti M., Biasiol G., Altamura S., Cortese R., De Francesco R., and Sollazzo M. Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 protease. Protein Eng. 10 (1997) 607-614
46. Martineau P., Guillet J.G., Leclerc C., and Hofnung M. Expression of heterologous peptides at two permissive sites of the MalE protein: antigenicity and immunogenicity of foreign B-cell and T-cell epitopes. Gene 113 (1992) 35-46
47. Miller J.H. A Short Course in Bacterial Genetics. Cold Spring Harbor (1992), Laboratory Press, Cold Spring Harbor, NY
48. Molla A., and Kohlbrenner W. Evolving therapeutic paradigms for HIV and HCV. Curr. Opin. Biotechnol. 14 (2003) 634-640
49. Nagel-Wolfrum K., Buerger C., Wittig I., Butz K., Hoppe-Seyler F., and Groner B. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol. Cancer Res. 2 (2004) 170-182
50. Norman T.C., Smith D.L., Sorger P.K., Drees B.L., O'Rourke S.M., Hughes T.R., Roberts C.J., Friend S.H., Fields S., and Murray A.W. Genetic selection of peptide inhibitors of biological pathways. Science 285 (1999) 591-595
51. Pawlotsky J.M. Hepatitis C virus resistance to antiviral therapy. Hepatology 32 (2000) 889-896
52. Perni R.B., Almquist S.J., Byrn R.A., Chandorkar G., Chaturvedi P.R., Courtney L.F., Decker C.J., Dinehart K., Gates C.A., Harbeson S.L., Heiser A., Kalkeri G., Kolaczkowski E., Lin K., Luong Y.P., Rao B.G., Taylor W.P., Thomson J.A., Tung R.D., Wei Y., Kwong A.D., and Lin C. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 50 (2006) 899-909
53. Poynard T., Yuen M.F., Ratziu V., and Lai C.L. Viral hepatitis C. Lancet 362 (2003) 2095-2100
54. Purcell R. The hepatitis C virus: overview. Hepatology 26 (1997) 11S-14S
55. Randall G., and Rice C.M. Interfering with hepatitis C virus RNA replication. Virus Res. 102 (2004) 19-25
56. Real E., Rain J.C., Battaglia V., Jallet C., Perrin P., Tordo N., Chrisment P., D'Alayer J., Legrain P., and Jacob Y. Antiviral drug discovery strategy using combinatorial libraries of structurally constrained peptides. J. Virol. 78 (2004) 7410-7417
57. Reiser M., Hinrichsen H., Benhamou Y., Reesink H.W., Wedemeyer H., Avendano C., Riba N., Yong C.L., Nehmiz G., and Steinmann G.G. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41 (2005) 832-835
58. Saphire E.O., Montero M., Menendez A., van Houten N.E., Irving M.B., Pantophlet R., Zwick M.B., Parren P.W., Burton D.R., Scott J.K., and Wilson I.A. Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies. J. Mol. Biol. 369 (2007) 696-709
59. Shaki-Loewenstein S., Zfania R., Hyland S., Wels W.S., and Benhar I. A universal strategy for stable intracellular antibodies. J. Immunol. Methods 303 (2005) 19-39
60. Sperandio D., Gangloff A.R., Litvak J., Goldsmith R., Hataye J.M., Wang V.R., Shelton E.J., Elrod K., Janc J.W., Clark J.M., Rice K., Weinheimer S., Yeung K.S., Meanwell N.A., Hernandez D., Staab A.J., Venables B.L., and Spencer J.R. Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease. Bioorg. Med. Chem. Lett. 12 (2002) 3129-3133
61. Steinkühler C., Biasiol G., Brunetti M., Urbani A., Koch U., Cortese R., Pessi A., and De Francesco R. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 37 (1998) 8899-8905
62. Steinkühler C., Koch U., Narjes F., and Matassa V.G. Hepatitis C virus protease inhibitors: current progress and future challenges. Curr. Med. Chem. 8 (2001) 919-932
63. Suzuki R., Suzuki T., Ishii K., Matsuura Y., and Miyamura T. Processing and functions of hepatitis C virus proteins. Intervirology 42 (1999) 145-152
64. Takeuchi T., Katsume A., Tanaka T., Abe A., Inoue K., Tsukiyama-Kohara K., Kawaguchi R., Tanaka S., and Kohara M. Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology 116 (1999) 636-642
65. Tsumoto K., Misawa S., Ohba Y., Ueno T., Hayashi H., Kasai N., Watanabe H., Asano R., and Kumagai I. Inhibition of hepatitis C virus NS3 protease by peptides derived from complementarity-determining regions (CDRs) of the monoclonal antibody 8D4: tolerance of a CDR peptide to conformational changes of a target. FEBS Lett. 525 (2002) 77-82
66. Ueno T., Misawa S., Ohba Y., Matsumoto M., Mizunuma M., Kasai N., Tsumoto K., Kumagai I., and Hayashi H. Isolation and characterization of monoclonal antibodies that inhibit hepatitis C virus NS3 protease. J. Virol. 74 (2000) 6300-6308
67. Umehara T., Fukuda K., Nishikawa F., Kohara M., Hasegawa T., and Nishikawa S. Rational design of dual-functional aptamers that inhibit the protease and helicase activities of HCV NS3. J. Biochem. (Tokyo) 137 (2005) 339-347
68. Vulliez-le Normand B., Saul F.A., Martineau P., Lema F., Hofnung M., and Bentley G.A. Maltodextrin-binding protein hybrids carrying epitopes from the preS2 region of hepatitis B virus: expression, antibody-binding and preliminary crystallographic studies. Protein Eng. 10 (1997) 175-180
69. Wyss D.F., Arasappan A., Senior M.M., Wang Y.S., Beyer B.M., Njoroge F.G., and McCoy M.A. Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening. J. Med. Chem. 47 (2004) 2486-2498
70. Xu C.W., and Luo Z. Inactivation of Ras function by allele-specific peptide aptamers. Oncogene 21 (2002) 5753-5757
71. Yi M., Bodola F., and Lemon S.M. Subgenomic hepatitis C virus replicons inducing expression of a secreted enzymatic reporter protein. Virology 304 (2002) 197-210
72. Yi M., Tong X., Skelton A., Chase R., Chen T., Prongay A., Bogen S.L., Saksena A.K., Njoroge F.G., Veselenak R.L., Pyles R.B., Bourne N., Malcolm B.A., and Lemon S.M. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor Reduced RNA replication fitness and partial rescue by second-site mutations. J. Biol. Chem. 281 (2006) 8205-8215
73. Zemel R., Berdichevsky Y., Bachmatov L., Benhar I., and Tur-Kaspa R. Inhibition of hepatitis C virus NS3-mediated cell transformation by recombinant intracellular antibodies. J. Hepatol. 40 (2004) 1000-1007
74. Zemel R., Gerechet S., Greif H., Bachmatove L., Birk Y., Golan-Goldhirsh A., Kunin M., Berdichevsky Y., Benhar I., and Tur-Kaspa R. Cell transformation induced by hepatitis C virus NS3 serine protease. J. Viral Hepatol. 8 (2001) 96-102
75. Zhu Z.Y., Zhong C.P., Xu W.F., Lin G.M., Ye G.Q., Ji Y.Y., Sun B., and Yeh M. PSMA mimotope isolated from phage displayed peptide library can induce PSMA specific immune response. Cell Res. 9 (1999) 271-280